LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/Zimmer Biomet Launches TrellOss-TC TLIF Platform
Spine

Zimmer Biomet Launches TrellOss-TC TLIF Platform

October 22, 2019 1 min read Premium comments

Advertisement

Zimmer Biomet Launches TrellOss-TC TLIF Platform
Courtesy of Zimmer Biomet Spine
#zimmerbiometSecondary#poroustitaniuminterbody#trelloss

Warsaw, Indiana-based Zimmer Biomet, a global leader in musculoskeletal healthcare, has launched the TrellOss-TC—Transforaminal Lumbar Interbody Fusion—(TLIF) Porous Titanium Interbody Platform.

TrellOss-TC, along with TrellOss-C (cervical) and TrellOss-TS (TLIF straight) that were launched in August 2019, marks Zimmer Biomet Spine’s first porous titanium implant platform manufactured through a 3D printing, additive manufacturing process. The company plans to extend the TrellOss platform with a series of lateral, anterior and stand-alone devices in 2020.

“We are very excited to announce the launch of the TrellOss Platform,” commented Jim Cloar, president of Zimmer Biomet Spine. “3D printing allows us to create a 7-micron surface roughness over the entire implant rather than on the endplates alone. Combined with varying pore sizes of 300, 500 and 700 microns, this surface technology creates an amicable environment for bone ingrowth.”

Jay Eaton, senior product manager, Posterior Interbody Solutions at Zimmer Biomet Spine, told OTW, “We chose pore sizes similar to that of bone (300, 500 and 700 microns) and that the various pores provide additional surface area on the implant. The 7-micron surface texturing creates an environment for potential cellular adhesion. We chose this implant design because of its combination of structured porosity and cellular relative surface texturing; this combination truly makes it a new foundation for growth.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy